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Abstract 
Purpose: To investigate detailed patient experiences specific to receiving vascular 
endothelial growth factor inhibitors (anti-VEGF) for wet Age-Related Macular 
Degeneration (wAMD), and to acquire a snapshot of the frequency of clinically 
significant levels of depression, anxiety and post-traumatic stress among patients and 
levels of burden in patients’ carers.  
Design: Observational cross-sectional mixed-methods study 
Methods: 300 patients with wAMD receiving anti-VEGF treatment and 100 patient 
carers were recruited. Qualitative data on patients’ experience of treatment were 
collected using a structured survey. Standardised validated questionnaires were used to 
quantify clinically significant levels of anxiety, depression, post-traumatic stress, as 
well as cognitive function and carers’ burden.  
Results: Qualitative data showed that 56% of patients (n =132) reported anxiety related 
to anti-VEGF treatment. The main sources of anxiety were fear of going blind due to 
intravitreal injections, and concerns about treatment effectiveness rather than around 
pain. From validated questionnaires, 17% of patients (n=52) showed clinical levels of 
anxiety, and 12% (n=36) showed clinical levels of depression. Depression levels, but 
not anxiety, were significantly higher in patients who received up to 3 injections 
compared to patients who received from 4 to 12 injections (ANOVA P=.027) and 
compared to patients who received more than 12 injections (ANOVA P=.001). 
Conclusions: Anti-VEGF treatment is often experienced with some anxiety related to 
treatment regardless of the number of injections received.  Clinical levels of depression 
seem to be more frequent in patients at early stages of anti-VEGF treatment. Strategies 
to improve patient experience of treatment and minimise morbidity are suggested. 
 
 
Key Words: Wet Age-Related Macular Degeneration; Anti-VEGF; Depression; 
Anxiety; Experience. 
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Introduction 
Age-related macular degeneration (AMD) is one of the leading causes of vision loss and 
blindness in people aged 50 years and older, particularly in the developed world (1,2). 
Currently, wet AMD (wAMD) is the only form of AMD that is treatable, usually involving 
the use of vascular endothelial growth factor inhibitors (anti-VEGF) such as bevacizumab, 
ranibizumab, or aflibercept (3,4). Anti-VEGF treatments are regarded as a generational 
breakthrough in the treatment of macular diseases such as wAMD (5). Recent studies have 
shown that anti-VEGF treatment can significantly reduce patients’ risk of severe visual 
impairment as it has great potential for halting disease progression (3-5). However, this 
treatment is administered by invasive intravitreal injections, often at the conclusion of 
lengthy, frequent and repeated visits after transport to a suitably equipped hospital.  
The specific act of these intraocular anti-VEGF injections can be experienced by patients as a 
stressful event, with anticipatory anxiety and expectations of pain and discomfort (6-8).  
Evidence on this topic is still limited due the lack of studies exploring the complexity and 
diversity of patient experiences of anti-VEGF treatment for wAMD (9). A recent review of 
the literature (9) only found 3 studies exploring in-depth patients’ experiences of receiving 
anti-VEGF treatments using qualitative designs (8,10,11). The remaining studies addressing 
the experience of receiving anti-VEGF treatment were mainly focused on medical aspects 
such as the anaesthetic’s effectiveness to prevent pain when receiving an intravitreal injection 
(12-17). The studies suggest that anticipatory anxiety associated with anti-VEGF treatment 
tends to be circumscribed to the first injections, i.e. at early stages of treatment (17,18). The 
aspects of anti-VEGF treatment in which patients have reported more discomfort and anxiety 
are (6-8,10,18): needle entry; application of drops; insertion of speculum; waiting for 
injection; experiences of pain, fear of losing sight, fear for the unknown and side effects. One 
qualitative study (11) also stressed the potential importance of other variables for the way 
patients experience anti-VEGF treatment and cope with anxiety and the fear for the 
“unknown”. These variables are: communication between healthcare professionals and 
patients, especially about treatment procedures; and the way service is delivered, with a 
special attention for anticipatory anxiety induced by waiting times before the injection. In 
another qualitative study on patient experience of anti-VEGF treatment (8), cautious 
optimism regarding treatment success and disease stabilization was found as a frequent and 
valid response to treatment from wet AMD patients.  There is, overall, a need for more 
research exploring the complexity of patient experience of anti-VEGF treatment to clarify 
reasons underlying patients’ anxieties when receiving regular intravitreal injections (9). 
The relationship between AMD and depression and anxiety has been well documented in 
literature (19-24). Research shows a wide prevalence range from 15.7% to 44% for 
depressive symptoms and 9.6% to 30.1% for anxiety symptoms among AMD patients (19). 
Previous studies have suggested that vision-related disability (caused by visual impairment) 
(25-28), visual acuity (29,30), and social support (31,32) can play an important role in the 
link between visual impairment and depression. Other studies have highlighted the link 
between ageing and depression (33) which might also play a role in the relationship between 
AMD and depression. However, most studies on depression associated with AMD were 
conducted prior to the implementation of anti-VEGF treatments or were conducted on general 
AMD patients (dry and wet) (22,34). This might be explained by the fact of anti-VEGF 
treatment is relatively recent and previous research on AMD and depression was conducted 
before the dissemination of anti-VEGF as the first line treatment for wAMD (34).  
Considering the positive effects of anti-VEGF to prevent further vision loss in wAMD 
patients, the question has been raised as to whether patients receiving anti-VEGF treatment 
might present a different prevalence of depression and anxiety (34,35). Existing studies in 
this field are still limited in generating evidence and often with low numbers (9,34). A recent 
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review on this topic (9) found four studies where the prevalence of depression was examined 
in patients receiving anti-VEGF treatments (22-24,36). Findings were preliminary but 
suggested that the wAMD patient group receiving anti-VEGF treatment still present higher 
rates of depression and anxiety in comparison with general population. Finally, previous 
research has also shown that despite depression and anxiety being common among adults 
with vision loss, they tend to not be tackled by health services and therefore remain untreated 
(36-39).  
The primary purpose of this study is to investigate the patient experience of receiving anti-
VEGF treatment for wAMD, with a particular focus on patient sources of anxiety related to 
anti-VEGF treatment. The secondary aim of this study is to achieve a snapshot of the 
frequency of clinical levels of anxiety, depression, and post-traumatic stress (PTS), among 
patients attending for treatment of wet AMD, and to explore levels of burden among patient 
carers. To the best of our knowledge there is no literature supporting the existence of any link 
between AMD or anti-VEGF and PTS, but we included the assessment of PTS as exploratory 
of any serious unmet mental health needs that could influence patients’ experience of 
treatment. Additionally, we want to explore clinical levels of depression and anxiety between 
patients with different number of injections received and between patients with different 
visual acuity. Mental health problems in our patient group could be related to their AMD, the 
injection treatments, ageing, personal history, burden of travel or other internal and external 
factors and we do not attempt to prove any specific link between anti-VEGF and 
psychological symptoms. Instead we aimed to explore any existent mental health needs in our 
patient group, exploring clinical levels of depression and anxiety across different patient sub-
groups to derive a general picture of patients’ mental health and whether these needs are 
being met by health services. With regard to patient carers, we also wanted to achieve a 
snapshot of the burden experienced by carers of a patient who regularly receives anti-VEGF 
treatment. Our study aims were built upon two premises: the fact our patient group is 
receiving regular invasive treatment that has been described as potential stressful; and the fact 
of AMD patients are generally considered at risk of having comorbid mental health problems 
that tend to not be addressed by health services. Our ultimate hope is that information from 
this study can be used to help managing the psychological as well as ophthalmic needs of our 
patients in AMD clinics.  
Literature on depression and anxiety among wAMD patients receiving anti-VEGF treatment 
is still very limited and scarce, which necessitates a more exploratory scope for our study. 
However, we hypothesise that patient anxiety related to anti-VEGF is more frequent among 
patients at early stages of treatment, i.e., in patients who have received up to 3 injections than 
in patients who are receiving treatment for longer, in light of what was suggested in previous 
studies (17,18). Additionally, we hypothesise that clinical levels of depression and anxiety 
are significantly more frequent in patients who are at early stages of treatment (who have 
received up to 3 injections) than in patients receiving treatment for longer, i.e., the higher the 
number of anti-VEGF injections received, the less frequent anxiety and depression are seen. 
Finally we also hypothesise that the frequency of clinical levels of depression and anxiety are 
negatively correlated with visual acuity, as previous studies suggested that depression is 
associated with poorer visual acuity in patients with vision disorders (29,30).  
 
Methods 
Ethics 
North West Research Ethics Committee (NHS, UK) approved study procedures (reference 
15/NW/0288). The study adheres to the tenets of the declaration of Helsinki. We offered all 
participants a participant information sheet, and obtained informed consent prior to 
recruitment.  
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Study Design 
We carried out an observational cross-sectional mixed-methods study. The qualitative strand 
used a structured survey to explore patient experience of receiving anti-VEGF treatment and 
sources of anxiety associated with this treatment. The quantitative strand of this study used 
standardised psychological instruments to investigate depression and anxiety, and post-
traumatic stress in our sample of patients and levels of burden among patients’ carers. This 
mixed-methods design allows us to combine the measurement of psychological health in 
patients undergoing treatment for wAMD (depression, anxiety and post-traumatic stress) with 
in-depth data (qualitative strand) that explores experience of treatment and sources of anxiety 
associated with treatment.  
 
Participants 
We invited consecutive patients with formal diagnoses of wAMD attending the macular 
treatment centre at Manchester Royal Eye Hospital to take part in the study. Patients and 
carers were recruited from May 2015 to November 2015. Inclusion criteria for patients were: 
to have a confirmed diagnosis of wAMD, to have received at least one anti-VEGF injection 
prior to the interview for this study, and to be followed-up in the macular treatment centre of 
the corresponding hospital. We included in our study patients who were receiving and who 
were not receiving psychological and psychiatric treatment. We excluded patients whose first 
anti-VEGF injection was on the day of interview and patients who were not able to 
communicate effectively. For carers the inclusion criteria was only to be carer of a patient 
currently receiving anti-VEGF treatment for wAMD. In our study, all researchers were 
blinded to carer-patient relationship, i.e., we interviewed carers without knowing who was the 
corresponding patient of each carer, in order to allow carers to be as open and honest as 
possible.   
 
Procedures 
Participants were approached by an experienced clinical psychologist (HS) on the same day 
they were scheduled to have the medical appointment and receive treatment.  All patients 
were invited to participate in an individual interview before receiving the injection, in a 
private room where all study instruments were administered. Participants were issued with a 
patient information sheet, and given the opportunity to ask questions about their participation. 
They provided written informed consent if they agreed to participate. Questionnaires and 
forms were read to patients who were unable to read as a result of their vision loss or having 
received topical eye medication. Carers of patients were approached by another researcher 
(NM) on the same day, following the same procedures.  
 
Measures for Qualitative Strand 
For the qualitative strand of this study, we were keen to acquire a broad range of information 
specific to AMD. A structured survey was developed from input provided by a patient and 
public involvement (PPI) group, previous literature on the topic, and considering our prior 
experience of dealing with AMD patients. The PPI event consisted of an informative meeting 
with wAMD patients, researchers and healthcare professionals who worked with these 
patients on a daily basis. The PPI group helped to identify key issues of patients’ perceptions 
and concerns about anti-VEGF treatment and the way it has been delivered, which shaped the 
development of the survey. The PPI meeting lasted 2 hours and was audio-recorded and 
transcribed to identify the main and key concerns raised by participants about the treatment 
for wet AMD and the way the treatment is being delivered by our service. Although our 
survey was built upon the main topics raised by PPI participants, we have also included 
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questions addressing topics that have been highlighted in previous literature on patient 
experience of anti-VEGF treatment (9), such as sources of anxiety related to anti-VEGF 
treatment, and experiences of pain when receiving an injection.  The final version of our 
survey comprised of 17 closed-ended questions addressing patients’ demographics, clinical 
data and experience and perception of anti-VEGF treatment, and one open-ended question 
addressing patient concerns and anxieties on the anti-VEGF treatment (for more details on 
the survey please see appendix A). Topics covered by the survey included anxieties and 
concerns about anti-VEGF treatment, treatment preferences and options, doctor/patient 
relationship, pain experienced when receiving treatment and perception of carer’s burden. 
 
Measures for Quantitative Strand 
We defined patients’ visual acuity (VA) as the best-corrected VA of the eye with better 
vision. Best-corrected VA was converted into the logarithm of the minimum angle of 
resolution during analysis. We divided patients into 3 groups, based on the World Health 
Organization (WHO) classification of visual impairment (40): no visual impairment or mild 
visual impairment (VA≥6/18), moderate impairment (6/60 < VA<6/18) and severe 
impairment (VA<6/60). 
Depression and anxiety were assessed by the Hospital Anxiety and Depression Scale (HADS) 
(41). HADS is a 14-item self-report scale, comprising two subscales evaluating levels of 
anxiety (HADS-Anxiety) and levels of depression (HADS-Depression). The HADS has been 
used extensively in the hospital setting as a standardised psychological screening tool for 
emotional disorders (41). Each subscale includes 7 items, generating possible scores of 0 to 
21 for anxiety (Cronbach's α = 0.89) and depression (Cronbach's α = 0.91). A score of 8 and 
above is widely used to indicate the presence of clinical levels of anxiety or depression that 
may warrant further psychological investigation (41,42).  
Post-traumatic stress (PTS) symptoms related to receiving an intravitreal injection was 
assessed by the Impact of Events Scale-Revised (IES-R) (43). IES-R is a validated measure 
of self-reported posttraumatic stress symptoms experienced in the past seven days in relation 
to a specific stressor (40). IES-R consists of 22 items, each ranging from 0 (“Not at all”) to 4 
(“Extremely”), with the total score ranging from 0 to 88. Three symptom clusters associated 
with post-traumatic stress are assessed with the IES-R, including intrusion, avoidance and 
hyperarousal. Intrusion relates to intrusive thoughts, nightmares and imagery associated with 
the traumatic event (8 items; Cronbach's α = 0.90), avoidance relates to avoidance of any 
feelings or situations (8 items; Cronbach's α = 0.95) and hyper-arousal is an inability to 
concentrate, anger, irritability and hypervigilance (6 items; Cronbach's α = 0.96). Higher 
scores indicate more symptoms of posttraumatic stress, with scores above 24 indicating the 
potential need for clinical assessment and care (43). 
The Mini-Mental State Examination (MMSE) (44) was used to assess patients’ cognitive 
status. MMSE consists of two sections: the first section requires oral responses regarding 
temporal and spatial orientation, memory and attention; the second section requires the 
subject to name simple objects, follow verbal written commands, write a sentence 
spontaneously, and copy two intersecting pentagons, in order to assess language and visuo-
spatial functions.  MMSE final score ranges from 0 to 30 (the maximum score). MMSE 
scores from 25 to 30 suggest a questionably significant degree of cognitive impairment. 
Scores from 21 to 24 indicate mild cognitive impairment. Scores from 10 to 20 suggest 
moderate cognitive impairment, and scores below 10 suggest severe cognitive impairment.  
We adjusted some vision-related tasks to make them suitable for patients with vision 
impairment: for the task “writing a sentence” we helped the patient to find the paper and 
writing space; for the task “reading a sentence” we provided larger letters printed in bold; and 
for “identifying a pen and a watch” we adjusted the distance of those objects to the patients’ 
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eyes. We only excluded the last MMSE task which consists of asking the patient to copy a 
pair of intersecting pentagons, as this task involves more complex visuospatial planning and 
executive skills. We anticipated that some patients would perform inaccurately in this task 
due to reduced visual acuity which would compromise the reliability of results. Final scores 
were adjusted from 0 (minimum) to 29 (maximum) because one point refers to the last test 
task involving the copy of a pair of pentagons. Cut-off scores were also adjusted, i.e., we 
used the original test cut-off scores minus 1 point. The internal consistency of the MMSE 
obtained Cronbach’s alphas of 0.82 in elderly patients admitted to a medical service and 0.84 
in elderly nursing home residents (44,45). 
The Burden Assessment Scale (BAS) (46) was used to assess burden in patients’ carers. BAS 
is a 19-item measure that evaluates burden in an objective way, that is, the amendment of 
caring for someone with limitations imposed on the level of activities and resources of the 
caregiver. BAS employs a 4-point scale (1–4), with higher scores indicating greater levels of 
caregiving burden. Cronbach’s alphas for the subscales and total scale were as follows: a = 
0.82 for limitation in activity, a = 0.64 for feelings of worry and guilt, a = 0.71 for social 
burden, and a = 0.81 for total scale. 
 
Data Analysis 
Results are presented mainly with descriptive statistics using SPSS software. We had no prior 
sample to perform power calculations. As part of pilot analyses, Chi-square test was used to 
investigate whether or not anxiety related to treatment is more frequent in patients who have 
received up to 3 injections than in patients who have received more injections, i.e., patients 
receiving treatment for longer. The basic assumptions for this statistical test were satisfied in 
that there were distinct categories and all expected frequencies were greater than 5. We 
created three sub-groups of patients who received up to 3 injections, i.e. patients who are at 
early stages of treatment (Group 1, n=21); patients who received 4 to 12 injections, i.e., 
patients who are not at early stages of treatment but are more experienced with treatment and 
are not yet regarded as chronically treated (Group 2, n= 119); and patients who have received 
more than 12 injections and therefore are more likely to be chronically treated with anti-
VEGF (Group 3, n=160). The choice of sub-groups was based upon patient and public 
involvement meetings and upon timeframes cited in previous literature indicating patient 
anxiety associated with earlier stages of treatment (17,18). Univariate ANOVA was used to 
investigate differences in HADS scores for depression and anxiety between all sub-groups of 
patients (G1, G2 and G3). Chi-square test was used to investigate differences in the frequency 
of patients with HADS scores indicating clinical levels of depression between all sub-groups 
of patients (G1, G2 and G3). Chi-square post-hoc analysis was performed using adjusted 
residuals (47) to investigate which sub-groups of patients present significant differences in 
number of cases of clinical levels of depression. The samples were from a number of 
independent groups and the variables were normally distributed with similar variance in each 
group. Pearson correlation was used to investigate associations between HADS scores and 
visual acuity (LogMAR), and between HADS scores and number of injections received.  
Data from the survey was analysed in terms of frequency of responses for each closed-ended 
question. The final open-ended question of the survey was analysed for the frequency of each 
source/type of anxiety related to anti-VEGF treatment that patients reported.     
 
Results 
Patient Characteristics  
We invited 345 patients and 100 carers to participate in our study. Of 345 patients 41 refused 
to participate and 4 were not eligible because they were not able to communicate effectively 
with the interviewer. A total of 300 wAMD patients and 100 carers gave their consent and 
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agreed to participate in this study. Patients’ demographic and clinical data are presented in 
Table 1. Our sample of patients had a higher percentage of women (59.7%), and patients who 
were receiving treatment for more than 1 year (72%). The great majority of patients (85%) 
had good visual acuity or mild visual impairment. More than 95% of our patients were not 
receiving any psychological or psychiatric support at the time of the interview.  
 
Please insert Table 1 here 
 
Qualitative Strand – Broad Experience of Receiving Anti-VEGF Treatment from Survey 
Patients’ experience of receiving anti-VEGF treatment is presented in table 2 and table 3. 
Generally patients reported a positive feedback on doctor/patient relationship and the quality 
of care received. Most patients were satisfied with the support received from the hospital and 
also satisfied with the information received about the condition and treatment. Most patients 
also preferred to rely on the doctors to make treatment decisions. With regard to patients’ 
treatment concerns and anxiety, we found that 132 patients (56%) reported some type of 
anxiety related to anti-VEGF treatment. Further analysis showed that the patients’ main 
concerns and sources of anxiety related to anti-VEGF treatment were: fear of going blind due 
to intravitreal injections / fear of the needle causing damage in the eye (n=118; 39.3%); hope 
the treatment works properly / fear of getting worse because the treatment didn’t work 
(n=111; 37%); waiting in the patient waiting room / anticipatory anxiety (n=104; 34.6%); and 
fear of the unknown in relation to treatment outcomes and disease progression (n=91; 30%). 
In contrast, anxiety around injection pain (n=10; 3.3%) were relatively infrequently raised. 
127 patients (42.3%) did report experiences of pain when receiving an intravitreal injection, 
but the level of pain was relatively minor with mean score of 2.4 (±3.17) on a scale from 0 to 
10 with 67% of patients experiencing a level of pain equal or below to 3 (scale 0 to 10). 
Among those patients who reported pain when receiving an injection, 42 patients (33%) 
experienced pain only during the initial treatment injection(s), 55 patients (43.3%) 
experienced pain half way through their treatment, and  30 patients (23.6%) experienced pain 
only during the last few injections received. More than half of patients (53.7%) reported to 
have expected more pain than they really experienced when receiving an intravitreal 
injection. 
 
Please insert Table 2 and Table 3 here 
 
Anxiety related to Anti-VEGF treatment and Number of Injections Received   
Frequency of anxiety related to treatment in each patient sub-group for the number of 
injections received is presented in Table 4. Chi-Square showed no significant differences 
(P>.05) in the frequency of anxiety related to anti-VEGF treatment between patients who 
have received different number of injections, i.e., between all patient sub-groups (G1, G2 and 
G3).   
 
Please insert Table 4 here 
 
Quantitative Strand – Clinical Levels of Depression, Anxiety, Post-traumatic stress and 
Carers Burden 
Results from the standardized measures on depression, anxiety, post-traumatic stress, 
cognitive function and burden are presented in Table 1. HADS-Anxiety scores indicated that 
17% (n=52) of all wAMD patients had clinical levels of anxiety, 10.6% (n=5) of which were 
receiving psychological or psychiatric treatment at the time of interview. HADS-Depression 
scores indicated that 12% (n=36) of all wAMD patients had clinical levels of depression, 9% 
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(n=3) of which were receiving psychological or psychiatric treatment for depression. 
Therefore 89% (n=47) of patients who showed anxiety, and 91% (n=33) of patients who 
showed depression were not receiving appropriate psychological and psychiatric treatment 
for their condition. 1 % (n=3) of patients showed symptoms of post-traumatic stress disorder 
according to the IES-R. Most patients (90.3%; n=271) did not exhibit impaired cognition 
according to MMSE. All patients were able to perform the administrated MMSE vision-
related tasks successfully. Finally, according to BAS scores, 73% (n=73) of carers reported 
little or no burden, 19% (n=19) reported mild to moderate burden, and 8% (n=8) reported 
moderate to severe burden. No carers reported severe burden. 
 
Please insert Table 5 here 
 
Depression and Anxiety Investigated for Number of Anti-VEGF Injections Received and 
Visual Acuity  
Table 5 displays HADS scores in different sub-groups of patients regarding the number of 
anti-VEGF injections received. HADS-Depression scores were significantly higher in 
patients who had received up to 3 injections (Group 1) in comparison with patients who had 
received from 4 to 12 injections (Group 2) (ANOVA P=.027), and in comparison with 
patients who had received more than 12 injections (Group 3) (ANOVA P=.001). No 
significant differences were found in HADS-Anxiety scores between the three sub-groups of 
patients for the number of injections received (ANOVA P=.22).  
Table 6 displays the frequency of patients with a HADS-Depression score indicating clinical 
levels of depression in the three sub-groups of patients (HADS-Depression≥8). Chi-square 
test showed significant differences between groups (P=.003). Chi-square post-hoc analysis 
indicated that the number of patients with clinical levels of depression were significantly 
higher in Group 1 (patients who had received up to 3 injections) (P=.002), considering the 
adjusted Bonferroni corrected P-value of .008.   
HADS-Depression scores were significantly but weakly correlated with number of anti-
VEGF injections received (R=-.126; P=.03). HADS-Anxiety scores were not significantly 
correlated with number of injections (P=.325). Both HADS-Anxiety (P=.536) and HADS-
Depression scores (P=.635) were not significantly correlated with VA (LogMAR).  
 
Please insert Table 6 here 
 
Discussion 
The qualitative findings of the study demonstrated that patients generally reported to have a 
good understanding of anti-VEGF treatment, and a good relationship with healthcare 
professionals. Additionally, they acknowledged the need for receiving treatment and its 
potential benefits for their eye health. However, despite presenting positive feedback on anti-
VEGF treatment, more than half of the patients reported anxiety associated with receiving 
anti-VEGF treatment. In addition, our findings suggest that the frequency of anxiety related 
to treatment is similar between patients who are at early stages of treatment, i.e., patients who 
had received up to 3 injections, and patients who are receiving treatment for longer. This 
finding rejects our hypothesis that patients anxiety related to treatment is higher in patients 
who have received up to 3 injections and suggests that the anxiety related to anti-VEGF 
might persist throughout the treatment, which is not consistent with some previous literature 
(17,18). A possible explanation for this finding is the fact of patients’ three most frequent 
sources of anxiety related to treatment in our study were related to fear of going blind due to 
injections, concerns about vision getting worse from treatment failure  and waiting in the 
waiting room. These sources of anxiety are known to be frequent in this patient group 
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(8,10,11) and are triggered by treatment preconceptions, and anticipatory anxiety induced by 
regular waiting times in the waiting area before receiving treatment (11). Further cohort 
studies will better clarify patient anxiety related to anti-VEGF treatment, in terms of variance 
throughout the treatment and identifying potential anxiety triggers. 
Previous literature has suggested that the main sources of patient discomfort and anxiety are 
related to the injection procedure and the fear of a needle causing damage in the eye 
(6,8,10,11). Our survey acknowledges this but suggests greater patient fears of going blind 
either as the final route of wAMD and / or as a consequence of an unexpected adverse event 
occurred during the injection, which is very unlikely to occur. These fears occurred despite 
patients having received routine information from the medical staff about the potential 
benefits of anti-VEGF treatment and the safety of treatment procedures. The findings from 
the survey suggest patients may benefit from additional and very specific information before 
they start the treatment with regard to the success rates of anti-VEGF treatment in halting 
disease progression, the disease process and how treatment can reduce the risk of becoming 
blind in the future. Additionally, it would be useful for patients to be informed that the needle 
in the eye will not be applied in the central area of the ocular globe, i.e., the patient will not 
see the needle coming into the eye.  Finally patients need to be better informed about low 
likelihood of serious problems following the treatment, and that most adverse effects can be 
easily manageable after the treatment. Further patient resources and/or communication skills 
training for health professionals would help to better inform patients.  
The quantitative finding of the study illustrated a considerable frequency of patients with 
clinical levels of depression and anxiety, and low percentage of patients with symptoms of 
post-traumatic stress. According to epidemiologic studies on depression and anxiety (48,49), 
the frequency of clinical levels of anxiety and depression we found in our patient group is 
higher than general population, and within the range of what has been found in studies on 
general AMD patients (dry and wet AMD) (19). However, it is also noticeable that the 
frequency of patients with clinical levels of anxiety that we found in our validated 
questionnaires (17%) is clearly lower than the frequency of patients reporting anxiety related 
to treatment in our survey (56%). This difference is explained by the concept that patient 
anxiety related to treatment does not necessarily have clinical value or entail clinical levels of 
anxiety, i.e., a patient can have concerns and anxiety about the treatment but not being 
clinically anxious.   
Another important issue was that most of our patients were not receiving any psychiatric or 
psychological treatment at the time of interview. These findings draw attention to the need of 
tackling mental health needs among adults with vision loss, especially in health services 
dedicated to provide care for ophthalmologic diseases. Previous research has highlighted the 
tendency for these needs to remain unaddressed (36-39), which might have a negative impact 
on patient healthy life-style, and eventually compromise medical treatment outcomes.  
The study results partially reject our previous hypothesis that the frequency of clinical levels 
of depression and anxiety is higher at early stages of anti-VEGF treatment. We only 
confirmed the hypothesis that the frequency of clinical levels of depression is higher in 
patients who were at early stages of treatment (had received up to 3 intravitreal injections), 
compared to patients who had received more than 3 injections, i.e., patients who were at later 
stages of treatment. This hypothesis is also supported by the correlation we found between 
the number of injections received and HADS-Depression scores. However, this finding 
should be confirmed in further studies conducted on a larger sample size, as our group 1 
sample was small and the correlation coefficient we found was significant but weak. Previous 
literature on this topic is very limited and inconclusive about the frequency of depression in 
patients at different anti-VEGF treatment stages (9,22,28,34). One possible hypothesis to 
explain why depression is higher in patients at early stages of treatment is the fact of AMD is 
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often seen as a threatening condition that entails further blindness (50). Patients recently 
diagnosed with wAMD can therefore have that expectation of going blind. Previous 
qualitative and mixed-methods studies on adults with serious vision disorders suggested that 
the fear of further vision loss and blindness can be an important source of emotional distress 
(32,51,52), which can ultimately lead to depression (32). In light of this, patients at early 
stages of anti-VEGF treatment might be at higher risk of having depression due to their fear 
of going blind because of wAMD. However, as anti-VEGF treatment proceeds, patients can 
become more optimistic about treatment success and disease stabilization (8). 
Patients in this study were on anti-VEGF therapy and the great majority of them had good 
visual acuity and did not have visual impairment according to the WHO’s criteria (40).  
We still found that a percentage of wAMD patients are clinically depressed and anxious 
within the same prevalence range found in previous studies conducted with adults with visual 
impairment (53-55). Additionally, we rejected our hypothesis that depression and anxiety are 
negatively correlated with visual acuity, which is not consistent with some previous literature 
suggesting that patients with lower visual acuity are more likely to suffer from depression 
than patients with better visual acuity (29,30). However this is possibly explained by the fact 
of the great majority of our patients did not have visual impairment and therefore they were 
not likely to suffer from vision-related disability which my triggers depression (25-28).  
Social support has been described as playing an important role in patient experience of illness 
and depression (31,32). Most of patient carers them did not report experience of burden while 
being carers of someone with wAMD. This finding is consistent with the fact that most of our 
patients didn’t perceive themselves as a source of burden for carers which might suggest that 
the majority of our patients had no issues with social support.  
Our study highlights common sources of anxiety related to the process of treatment for wet 
macular degeneration and an awareness of these would be useful for any clinician to improve 
the patient experience with wAMD. It is suggested that some patient anxiety such as the fear 
of going blind due to injections, fear for the unknown and fear of getting worse, might be 
attenuated with effective communication from healthcare professionals and some counselling 
if needed. To ask patients about their preconceptions and expectations of treatment and 
prepare them for initiating anti-VEGF treatment, explaining how injections are administrated 
and how unlikely it is to go blind because of injections, might help patients to cope with 
treatment. Physicians should also be aware of the prevalence of undiagnosed anxiety and 
depression in their AMD patients and be alert to the opportunity to manage this.  Inclusion of 
standardized tools to screen wAMD patients for symptoms of anxiety and depression in the 
clinical routine of a macular treatment unit could help to better identify such patients. This 
should be applied irrespective of how long patients have been having injections.  
In the current study, some limitations need to be acknowledged. This is a cross-sectional 
study and therefore it is more limited in providing insights into dynamic changes in clinical 
levels of depression and anxiety over time which would be valuable to understand these 
symptoms in our sample. In our study there was potential for selective bias in data collection 
because we were not able to identify patients who discontinued treatment after initial 
injection and patients with very good response (no recurrence after the first loading phase of 
3 injections) or very poor response to treatment (vision drop below 6/60 despite treatment), 
because these patients’ follow-up is usually carried out outside the hospital. One of the 
researchers who collected data for this study (HS) also contributed to the study design and 
data analysis which may have entailed some bias to the results of study. Furthermore some of 
the researchers involved in the study have had prior clinical experience with wAMD patients, 
and therefore may hold preconceptions about patients’ coping behaviours with treatment, 
which may also contribute as a source of bias. In our study the researcher were blinded to the 
patient-carer relationship, and did not link carers to the corresponding patients to ensure they 
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would provide a more authentic input of their experiences and perceptions of being a carer. 
However, a limitation of this was that we were not able to know about the potential 
importance of patients’ social support for their experience of treatment and for the occurrence 
of clinical levels of depression. Finally, the authors were not able to have data on the clinical 
characteristics of the 41 patients who refused to participate and therefore didn’t provide 
informed consent, and the 4 patients who were excluded because they were unable to 
communicate effectively with the interviewer. 
In conclusion, this study represents one of the largest and most detailed examinations of 
patients undergoing anti-VEGF therapy to date. We found that although anti-VEGF 
treatments themselves are generally well-accepted, particular causes of anxiety exist which 
could potentially be reduced by improved education and minor alterations in practice. Our 
additional study using validated objective questionnaires demonstrated that in our examined 
population, a substantial percentage of patients with wAMD receiving anti-VEGF treatment 
had undiagnosed clinical levels of anxiety and depression, despite the good visual acuity and 
the promising outcomes offered by anti-VEGF treatment in preventing further visual 
impairment. Doctors should be vigilant to this finding that might impair patients’ quality of 
life and consider measures to detect and address this. Further longitudinal studies and 
controlled trials are needed to provide a more in-depth understanding about depression and 
anxiety in wAMD patients and to aid development of new intervention tools, at both the 
patient and clinical level, aiming to reduce these symptoms and to improve the well-being of 
patients receiving anti-VEGF treatment.     
 
Abbreviations and Acronyms: 
wAMD: Wet Age-Related Macular Degeneration; Anti-VEGF: Vascular endothelial growth 
factor inhibitors; HADS: Hospital Anxiety and Depression Scale; IES-R: Impact of Events 
Scale Revised; MME: Mini-Mental State Examination; VA: Visual Acuity;  BAS: Burden 
Assessment Scale 
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Table 1 – Demographical and Clinical Data 
Variable No. (%) Range Mean ± SD 
Age   56-95 80±7.4 
Gender Female 179 (59.7%)   
Male 121 (40.3%) 
Years of education <10 193 (64.3%) 4-21 10.8±2.5 
≥10 107 (35.7%) 
Relationship status Single 22 (7.3%)  
Married 122 (40.7%) 
Widowed 123 (41%) 
Cohabited 7 (2.3%) 
Divorced 36 (8.7%) 
Visual acuity (LogMAR) Good VA / Mild visual 
impairment (≥6/18) 
255 (85%) 
 
0.02-1.0 0.6±0.26 
Moderate VA 
(6.60≤VA<6/18) 
42 (14%) 
Poor VA (<6/60) 3 (1%) 
Type of anti-VEGF 
treatment 
Ranibizumab 120 (40%)  
Aflibercept 175 (58.3%) 
Bevacizumab 5 (1.6%) 
Elapsed time since the first 
anti-VEGF injection 
(Treatment Duration) 
≤ 1 Year 84 (28%) 0-96 30.9±24 
> 1 Year 216 (72%) 
Number of injections 
received to date 
  1-66 16.6±11.6 
Receiving any type of 
psychiatric or 
psychological treatment 
Yes 13 (4,3%)  
No 287 (95,7%) 
Symptoms of Clinical 
Depression (HADS-D) 
No symptoms of depression 264 (88%) 
Symptoms of depression 36 (12%) 
Symptoms of Clinical 
Anxiety (HADS-A) 
No symptoms of anxiety 248 (82.7%) 
Symptoms of anxiety 52 (17.3%) 
Symptoms of PTS (IES-R) No symptoms of PTS 297 (99%) 
Symptoms of PTS 3 (1%) 
Cognitive Impairment No cognitive impairment 271 (90.3%)  
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(MMES) Mild cognitive impairment 25 (8.3%) 
Moderate to severe 
cognitive impairment 
4 (1.3%) 
Carers’ Perception of 
Burden (BAS) 
Little or no burden (0-20) 73 (73%) 0-55 14.4±13.07 
Mild to moderate burden 
(21-40) 
19 (19%) 
Moderate to severe burden 
(41-60) 
8 (8%) 
Severe burden (61-88) 0 
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Table 2 Results from Survey about Patient Experiences of Anti-VEGF treatment 
Survey Topic Sub-Topics No.(%) 
 
Anxiety related to anti-VEGF Treatment 
Anxiety / concerns related to 
treatment not reported 
132 (44%) 
Anxiety / concerns related to 
treatment reported 
168 (56%)   
Preferences about 
the treatment 
Hospital Visits Prefer having fewer hospital 
visits 
163 (54.3%) 
Don’t mind about the number 
of hospital visits 
137 (45.7%) 
Frequency of 
Intravitreal Injections 
Prefer receiving less frequent 
injections 
174 (58%) 
Don’t mind about the 
frequency of injections 
126 (42%) 
Expectation of Pain before start the 
Treatment 
No pain expected 128 (42.7%) 
Pain expected 161 (53.7%) 
Experience of Pain When Receiving an 
Intravitreal Injection 
No painful experience 162 (54%) 
One or more painful 
experiences 
127 (42.3%) 
Doctor/patient 
relationship 
Understanding of 
Treatment Options 
Good understanding of the 
different treatment options 
192 (64%) 
Poor understanding of the 
different treatment options 
21 (7%) 
Have only been told about 
one treatment option 
87 (29%) 
Making Decisions on 
the Eye Treatment  
Prefer just rely on the doctors 
for making decisions on the 
AMD treatment  
197 (65.7%) 
Prefer to be more in charge 
for making decisions on the 
AMD treatment 
8 (2.7%) 
Both (to rely on the doctors 
and to be in charge for 
making decisions)  
38 (31.7%) 
Contradictory Have received contradictory 22 (7.3%) 
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Information about the 
Condition and 
Treatment  
information about the 
diagnosis and treatment 
Did not have received 
contradictory information 
about the diagnosis and 
treatment 
277 (92.3%) 
Satisfaction with the 
support received from 
the hospital 
Some disappointment 38 (12.7%) 
Not disappointed 262 (87.3%) 
Explanation about 
treatments and exams 
Insufficient 35 (11.7%) 
Good 265 (88.3%) 
Perception of 
carer’s burden 
The carer has been burdened with hospital visits 44 (14.6%) 
The carer has not been burdened with hospital visits 130 (43.3%) 
Not applicable / no carer 126 (42%) 
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Table 3 Results from Survey about Patient Concerns and Sources of Anxiety Related to Anti-VEGF 
Treatment 
Concerns / Anxieties Associated with anti-VEGF Treatment No.(% of total sample) 
Fear of going bling due to injections / fear of the needle in the eye 118 (39.3%)  
Hope the treatment works properly / Fear of getting worse 
because the treatment didn’t work (treatment effectiveness) 
111 (37%) 
Waiting in the waiting room / Anticipatory anxiety  104 (34.7%) 
Fear of the unknown in relation to treatment outcomes and 
disease progression 
91 (30%) 
Anxiety caused by being in the eye hospital for a medical 
appointment, exam or eye-treatment  
52 (17.3%) 
Fear of pain when receiving an injection 10 (3.3%) 
Fear of side effects 8 (2.6%) 
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Table 4 – Frequency of Anxiety related to Anti-VEGF Treatment between Sub-Groups of 
Patients   
 G1: Up to 3 
injections 
received 
(N=21) 
 
G2: From 4 to 
12 injections 
received 
(N=119) 
G3: More than 
12 injections 
received 
(N=160) 
P-value*  
 
Patients who reported 
anxiety related to 
treatment (N=168) 
 
14 (66,7%) 64 (53,8%) 90 (56,3%) .546 
Patients who did not 
report anxiety related 
to treatment (N=132) 
 
7 (33,3%) 55 (46,2%) 70 (43,8%) 
G: Sub-Group of Patients; *Chi-Square test 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 5 – HADS scores in Sub-Groups of Patients    
 G1: Up to 3 
injections 
received 
(N=21) 
 
G2: From 4 to 
12 injections 
received 
(N=119) 
G3: More than 
12 injections 
received 
(N=160) 
P-value* 
between 
G1-G2 
 
P-value* 
between 
G1-G3 
 
P-value* 
between 
G2-G3 
 
HADS-Anxiety (±SD) 
 
5.1±3.9 3.8±4.1 3.56±3.51 .34 .19 .83 
HADS-Depression (±SD) 
 
5.8±4.5 3.7±3.8 2.9±2.9 .027** .001** .11 
G: Sub-Group of Patients; VA: Visual Acuity; VI: Visual Impairment 
* Univariate ANOVA; **P<0.05 
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Table 6 – Frequency of Clinical Levels of Depression between Sub-Groups of Patients   
 G1: Up to 3 
injections 
received 
(N=21) 
 
G2: From 4 
to 12 
injections 
received 
(N=119) 
 
G3: More than 
12 injections 
received 
(N=160) 
P Value* 
Patients with 
Clinical Levels 
of Depression 
(HADS-D≥8) 
 
7 (33,3%) 
P=.001** 
16 (13,4%) 
P=.54** 
13 (8,1%) 
P=.03** 
.003 
* Chi-Square Test before Post-Hoc analysis; ** Chi-Square Post-Hoc Analysis (Adjusted Bonferroni Corrected P-value=.008)      
